| 11.9781 0.058 (0.49%) | 11-11 12:28 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.24 | 1-year : | 16.64 |
| Resists | First : | 12.19 | Second : | 14.24 |
| Pivot price | 10.69  |
|||
| Supports | First : | 10.5 | Second : | 9.46 |
| MAs | MA(5) : | 11.63 |
MA(20) : | 10.57 |
| MA(100) : | 11.58 |
MA(250) : | 10.4 |
|
| MACD | MACD : | 0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 93 |
D(3) : | 91 |
| RSI | RSI(14): 61.8 |
|||
| 52-week | High : | 15.03 | Low : | 8.01 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ZVRA ] has closed below upper band by 10.7%. Bollinger Bands are 33% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 12 - 12.07 | 12.07 - 12.12 |
| Low: | 11.39 - 11.46 | 11.46 - 11.52 |
| Close: | 11.8 - 11.92 | 11.92 - 12.03 |
Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH). Their lead product candidate, KP1077, which is a prodrug of d-methylphenidate (known as serdexmethylphenidate), is currently in Phase II clinical trials for the treatment of both IH and narcolepsy. Another key prodrug candidate, KP879, is also advancing through Phase II studies for stimulant use disorder. In addition to its pipeline, Zevra has successfully secured FDA approval for two products: AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company's product portfolio also includes arimoclomol, and it holds collaboration and licensing agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Formerly known as KemPharm, Inc., the company officially rebranded to Zevra Therapeutics, Inc. in February 2023.
Tue, 10 Nov 2026
FMR LLC Adds Zevra Therapeutics Inc (ZVRA) Stake -- Shares Trade 41% Below GF Value - GuruFocus
Wed, 04 Nov 2026
Zevra Therapeutics, Inc. Q3 2026 Earnings Call Summary - Yahoo Finance
Wed, 04 Nov 2026
Zevra Therapeutics Inc (ZVRA) (Q3 2026) Earnings Call Highlights: Revenue Jumps 45% as MIPLYFFA ... - Yahoo Finance
Tue, 20 Oct 2026
Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call - GlobeNewswire
Thu, 15 Oct 2026
Zevra Therapeutics: Cash Plus A Drug Priced Below Its Rival's Deal (NASDAQ:ZVRA) - Seeking Alpha
Thu, 06 Aug 2026
Zevra Therapeutics Q2 Earnings Call Highlights - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 60 (M) |
| Shares Float | 54 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 80.3 (%) |
| Shares Short | 6,230 (K) |
| Shares Short P.Month | 5,740 (K) |
| EPS | 1.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.01 |
| Profit Margin | 52.7 % |
| Operating Margin | 30.6 % |
| Return on Assets (ttm) | 9.9 % |
| Return on Equity (ttm) | 41.9 % |
| Qtrly Rev. Growth | 44.9 % |
| Gross Profit (p.s.) | 2.37 |
| Sales Per Share | 2.48 |
| EBITDA (p.s.) | 0.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 39 (M) |
| Levered Free Cash Flow | 51 (M) |
| PE Ratio | 9.81 |
| PEG Ratio | 10.6 |
| Price to Book value | 2.97 |
| Price to Sales | 4.82 |
| Price to Cash Flow | 18.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|